Abstract
The increasing incidence of glaucoma and other ophthalmic diseases associated with elevated intraocular pressure has spurred the development of improved treatment strategies and therapies, aiming for better patient adherence and reduced treatment burden. While travoprost, a highly effective topical prostaglandin FP analogue, is frequently prescribed for patients with increased intraocular pressure, it presents challenges such as complex dosing regimens, poor adherence, and an increased risk of side effects stemming from chronic topical use. This comprehensive narrative review systematically investigates the contemporary status of travoprost intraocular implant, a device specifically engineered for sustained drug delivery to overcome the limitations of conventional topical travoprost formulations.The review synthesizes findings from studies discussing these implants and critically analyses the safety, efficacy profiles and patient tolerability detailed, including the two recent Phase 3 trials that led to its FDA approval, contextualizing them against other treatment modalities and therapies.While the advent of the iDose TR device marks a significant mark in the treatment and management of glaucoma and OHT, this review briefly explores other avenues for building on this technology and its potential impact on the future of glaucoma care.